Is facilitating pancreatic beta cell regeneration a valid option for clinical therapy?

Cell Transplantation

Volumn 15, Issue SUPPL. 1, 2006, Pages

  Trucco, Massimo ^a  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Autoimmunity; Beta cell precursors; Beta cell regeneration; Tolerization; Type 1 diabetes

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ALLELE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELL DESTRUCTION; CELL REGENERATION; CHIMERA; CONFERENCE PAPER; DISEASE PREDISPOSITION; GENETIC PREDISPOSITION; HEMATOPOIETIC STEM CELL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RELIABILITY; TRANSGENE;

TACCA LEONTOPETALOIDES;

EID: 33745200792     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/000000006783982322     Document Type: Conference Paper

References (49)

1. Acha-Orbea, H.; McDevitt, H. O. The first external domain of the nonobese diabetic mouse class II I-A β chain is unique. Proc. Natl. Acad. Sci. USA 84:2435-2439; 1987.
2. Andre-Schmutz, I.; Hindelang, C.; Benoist, C.; Mathis, D. Cellular and molecular changes accompanying the progression from insulitis to diabetes. Eur. J. Immunol. 29: 245-255; 1999.
3. Atkinson, M. A.; Leiter, E. H. The NOD mouse model of type 1 diabetes: As good as it gets? Nat. Med. 5:601-604; 1999.
4. Bach, J. F. Insulin-dependent diabetes mellitus as an autoimmune disease. Endocr. Rev. 15:516-542; 1994.
5. Bell, E.; Cao, X.; Moibi, J. A.; Greene, S. R.; Young, R.; Trucco, M.; Gao, Z.; Matschinsky, F. M.; Deng, S.; Markman, J. F.; Naji, A.; Wolf, B. A. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 52:2731-2739; 2003.
6. Bertera, S.; Geng, X.; Tawadrous, Z.; Bottino, R.; Balamurugan, A. N.; Rudert, W. A.; Drain, P.; Watkins, S. C.; Trucco, M. Body window-enabled in vivo multicolor imaging of transplanted mouse islets expressing an insulin-timer fusion protein. BioTechniques 35:718-722; 2003.
7. Bonner-Weir, S. Life and death of the pancreatic beta cells. Trends Endocrinol. Metab. 11:375-378; 2000.
8. Bottino, R.; Trucco, M. Multifaceted therapeutic approaches for a multigenic disease. Diabetes 54:S79-S86; 2005.
9. Chatenoud, L. CD3-specific antibody-induced active tolerance: From bench to bedside. Nat. Rev. Immunol. 3: 123-132; 2003.
10. Davies, J. L.; Kawaguchi, Y.; Bennett, S. T.; Copeman, J. B.; Cordell, H. J.; Pritchard, L. E.; Reed, P. W.; Gough, S. C. L.; Jenkins, S. C.; Palmer, S. M.; Balfour, K. M.; Rowe, B. R.; Farrall, M.; Barnett, A. H.; Bain, S. C.; Todd, J. A. A genome-wide search for human type 1 diabetes susceptibility genes. Nature 371:130-136; 2002.
11. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. 329:977-986; 1993.
12. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 22:99-111; 1999.
13. Farilla, L.; Hui, H.; Bertolotto, C.; Kang, E.; Bulotta, A.; Di Mario, U.; Perfetti, R. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 143:4397-4408; 2002.
14. Hanson, M. S.; Cetkovic-Cvrlje, M.; Vijayakumar, K. R.; Atkinson, M. A.; Maclaren, N. K.; Singh, B.; Elliott, J. F.; Serreze, D. V.; Leiter, E. H. Quantitative thresholds of MHC class II I-E expressed on hemopoietically derived antigen-presenting cells in transgenic NOD/Lt mice determine level of diabetes resistance and indicate mechanism of protection. J. Immunol. 157:1279-1287; 1996.
15. Hering, B. J.; Ricordi, C. Results, research priorities, and reasons for optimism; islet transplantation for patients with type 1 diabetes. Graft 2:12-27; 1999.
16. Hess, D.; Li, L.; Martin, M.; Sakano, S.; Hill, D.; Strutt, B.; Thyssen, S.; Gray, D. A.; Bhatia, M. Bone marrow-derived stem cells initiate pancreatic regeneration. Nat. Biotechnol. 21:763-770; 2003.
17. Iwakoshi, N. N.; Mordes, J. P.; Markees, T. G.; Phillips, N. E.; Rossini, A. A.; Greiner, D. L. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner. J. Immunol. 164:512-521; 2000.
18. Karges, B.; Durinovic-Bello, I.; Heinze, E.; Boehm, B. O.; Debatin, K-M.; Karges, W. Complete long-term recovery of β-cell function in autoimmune type 1 diabetes after insulin treatment. Diabetes Care 27:1207-1208; 2004.
19. Lechner, A.; Yang, Y. G.; Blacken, R. A.; Wang, L.; Nolan, A. L.; Habener, J. F. No evidence for significant transdifferentiation of bonemarrow into pancreatic β-cells in vivo. Diabetes 53:616-623; 2004.
20. Lee, K. L.; Wucherpfennig, K. W.; Wiley, D. C. Structure of a human insulin peptide/ HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat. Immunol. 2:501-507; 2001.
21. Li, H.; Kaufman, C. L.; Boggs, S. S.; Johnson, P. C.; Patrene, K. D.; Ildstad, S. T. Mixed allogeneic chimerism induced by a sublethal approach prevents autoimmune diabetes and reverses insulitis in nonobese diabetic (NOD) mice. J. Immunol. 156:380-388; 1996.
22. Lund, T.; O'Reilly, L.; Hutchings, P.; Kanagawa, O.; Simpson, E.; Gravely, R.; Chandler, P.; Dyson, D.; Picard, J. K.; Edwards, A.; Kioussis, D.; Cooke, A. Prevention of insulin-dependent diabetes mellitus in non-obese diabetic mice by transgenes encoding modified I-A β-chain or normal I-E α-chain. Nature 345:727-729; 1990.
23. Machen, J.; Harnaha, J.; Lakomy, R.; Styche, A.; Trucco, M.; Giannoukakis, N. Antisense oligonucleotides downregulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J. Immunol. 173:4331-4341; 2004.
24. McDevitt, H. O. Closing in on type 1 diabetes. N. Engl. J. Med. 345:1060-1061; 2001.
25. Morel, P.; Dorman, J.; Todd, J.; McDevitt, H.; Trucco, M. Aspartic acid at position 57 of the HLA DQ-beta chain protects against type I diabetes: A family study. Proc. Natl. Acad. Sci. USA 85:8111-8115; 1988.
26. Ogawa, N.; List, J. F.; Habener, J. F.; Maki, T. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 53:1700-1705; 2004.
27. Okabe, M.; Ikawa, M.; Kominami, K.; Nakanishi, T.; Nishimune, Y. "Green mice" as a source of ubiquitous green cells. FEBS Lett. 407:313-319; 1997.
28. Paris, M.; Bernard-Kargar, C.; Berthault, M. F.; Bouwens, L.; Ktorza, A. Specific and combined effects of insulin and glucose on functional pancreatic β-cell mass in vivo and in adult rats. Endocrinology 144:2717-2727; 2003.
29. Phelps, C. J.; Koike, C.; Vaught, T. D.; Boone, J.; Wells, K. D.; Chen, S-H.; Ball, S.; Specht, S. M.; Polejaeva, I. A.; Monahan, J. A.; Jobst, P. M.; Sharma, S. M.; Lamborn, A. E.; Garst, A. S.; Moore, M.; Demetris, A. J.; Rudert, W. A.; Bottino, R.; Bertera, S.; Trucco, M.; Starzl, T. E.; Dai, Y.; Ayares, D. L. Production of α1,3galactosyltransferase deficient pigs. Science 299:411-414; 2003.
30. Pietropaolo, M.; Trucco, M. Major Histocompatibility locus and other genes that determine the risk of development of insulin-dependent diabetes mellitus. In: LeRoith, D.; Taylor, S.; Olefsky, J. M., eds. Diabetes mellitus: A fundamental and clinical text, 3rd ed. Philadelphia, PA: J. B. Lippincott Co.; 2004:539-556; 2004.
31. Ricordi, C.; Zeng, Y. J.; Alejandro, R.; Tzakis, A.; Venkataramanan, R.; Fung, J.; Bereiter, D.; Mintz, D. H.; Starzl, T. E. In vivo effect of FK506 on human pancreatic islets. Transplantation 52:519-526; 1991.
32. Ricordi, C.; Strom, T. B. Clinical islet transplantation: Advances and immunological challenges. Nat. Rev. Immunol. 4:259-268; 2004.
33. Robertson, R. P.; Davis, C.; Larsen, J.; Stratta, R.; Sutherland, D. E. American Diabetes Association: Pancreas transplantation for patients with type 1 diabetes. Diabetes Care 26(Suppl. 1):S120; 2003.
34. Robertson, R. P. Islet transplantation as a treatment for diabetes-a work in progress. N. Engl. J. Med. 350:694-705; 2004.
35. Rother, K. L; Harlan, D. M. Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. J. Clin. Invest. 114:877-883; 2004.
36. Ryu, S.; Kodama, S.; Ryu, K.; Schoenfeld, D. A.; Faustman, D. L. Reversal of established autoimmune diabetes by restoration of endogenous β cell function. J. Clin. Invest. 108:63-72; 2001.
37. Shapiro, A. M.; Lakey, J. R.; Ryan, E. A.; Korbutt, G. S.; Toth, E.; Toth, E.; Warnock, G. L.; Kneteman, N. M.; Rajotte, R. V. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N. Engl. J. Med. 343:230-238; 2000.
38. Sutherland, D. E.; Sibley, R.; Xu, X. Z.; Michael, A.; Srikanta, A. M.; Taub, F.; Najarian, J.; Goetz, F. C. Twinto-twin pancreas transplantation: Reversal and reenactment of the pathogenesis of type I diabetes. Trans. Assoc. Am. Physicians 97:80-87; 1984.
39. Tamura, K.; Fujimura, T.; Tsutsumi, T.; Nakamura, K.; Ogawa, T.; Atumaru, C.; Hirano, Y.; Ohara, K.; Ohtsuka, K.; Shimomura, K.; et al. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic β-cell. Transplantation 59: 1606-1615; 1995.
40. Tian, C.; Bagley, J.; Cretin, N.; Seth, N.; Wucherpfennig, K. W.; Iacomini, J. Prevention of type 1 diabetes by gene therapy. J. Clin. Invest. 114:969-978; 2004.
41. Todd, J. A.; Bell, J. I.; McDevitt, H. O. HLA-DQ beta gene contributes to susceptibility and resistance in insulin-dependent diabetes mellitus. Nature 329:599-604; 1987.
42. Tomita, Y.; Sachs, D. H.; Khan, A.; Sykes, M. Additional monoclonal antibody (mAB) injections can replace thymic irradiation to allow induction of mixed chimerism and tolerance in mice receiving bone marrow transplantation after conditioning with anti-T cell mABs and 3-Gy whole body irradiation. Transplantation 61:469-477; 1996.
43. Trucco, M. Regeneration of the pancreatic beta cell. J. Clin. Invest. 115:5-12; 2005.
44. Trucco, M.; Giannoukakis, N. Type 1 diabetes: MHC tailored for diabetes cell therapy. Gene Ther. 12:553-554; 2005.
45. Trucco, M. To be, or not to be Asp 57, that is the question. Diabetes Care 15:705-715; 1992.
46. von Herrath, M.; Homann, D. Islet regeneration needed for overcoming autoimmune destruction-considerations on the pathogenesis of type 1 diabetes. Pediatr. Diabetes 5(Suppl. 2):23-28; 2004.
47. Zheng, X.; Sánchez-Fueyo, A.; Sho, M.; Domenig, C.; Sayegh, M.; Strom, T. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 19:503-514; 2003.
48. Zorina, T. D.; Subbotin, V. M.; Bertera, S.; Alexander, A.; Haluszczak, C.; Styche, A.; Gambrell, B.; Bottino, R.; Trucco, M. Tecovery of the endogenous beta cell function in autoimmune diabetes. Stem Cells 21:377-388; 2003.
49. Zorina, T. D.; Subbotin, V. M.; Bertera, S.; Alexander, A.; Styche, A. J.; Trucco, M. Distinct characteristics and features of allogeneic chimerism in the NOD mouse model of autoimmune diabetes. Cell Transplant. 11:113-123; 2002.